USANA Health Sciences (NYSE:USNA) Given New $46.00 Price Target at DA Davidson

USANA Health Sciences (NYSE:USNA) had its price target decreased by investment analysts at DA Davidson from $48.00 to $46.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. DA Davidson’s price objective would indicate a potential upside of 2.06% from the stock’s current price. DA Davidson also issued estimates for USANA Health Sciences’ Q2 2024 earnings at $0.68 EPS.

Separately, StockNews.com raised USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 12th.

USANA Health Sciences Stock Up 0.7 %

USNA stock opened at $45.07 on Tuesday. The company has a market cap of $865.34 million, a P/E ratio of 14.04, a PEG ratio of 1.38 and a beta of 0.94. USANA Health Sciences has a twelve month low of $41.45 and a twelve month high of $69.60. The business has a fifty day moving average of $46.42 and a 200-day moving average of $48.05.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.35. USANA Health Sciences had a return on equity of 12.80% and a net margin of 6.88%. The business had revenue of $221.08 million during the quarter, compared to analysts’ expectations of $206.70 million. As a group, equities research analysts anticipate that USANA Health Sciences will post 2.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Daniel A. Macuga sold 3,791 shares of USANA Health Sciences stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $47.14, for a total transaction of $178,707.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other USANA Health Sciences news, insider Daniel A. Macuga sold 3,791 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $47.14, for a total value of $178,707.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO G Doug Iiekking sold 5,198 shares of the business’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $44.76, for a total value of $232,662.48. The disclosure for this sale can be found here. Insiders sold a total of 34,286 shares of company stock valued at $1,634,010 over the last three months. Company insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. CWM LLC grew its stake in USANA Health Sciences by 21.8% in the first quarter. CWM LLC now owns 1,543 shares of the company’s stock valued at $75,000 after acquiring an additional 276 shares during the period. New York State Common Retirement Fund grew its stake in USANA Health Sciences by 1.2% in the fourth quarter. New York State Common Retirement Fund now owns 24,500 shares of the company’s stock valued at $1,313,000 after acquiring an additional 279 shares during the period. Swiss National Bank grew its stake in USANA Health Sciences by 1.2% in the third quarter. Swiss National Bank now owns 25,500 shares of the company’s stock valued at $1,495,000 after acquiring an additional 300 shares during the period. Rhumbline Advisers grew its stake in USANA Health Sciences by 1.4% in the third quarter. Rhumbline Advisers now owns 34,942 shares of the company’s stock valued at $2,048,000 after acquiring an additional 496 shares during the period. Finally, Strs Ohio boosted its position in shares of USANA Health Sciences by 4.8% during the third quarter. Strs Ohio now owns 10,900 shares of the company’s stock worth $638,000 after buying an additional 500 shares during the period. 54.25% of the stock is owned by institutional investors and hedge funds.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.